An FDA advisory committee is meeting on Thursday to discuss whether flibanserin — a drug sometimes nicknamed ‘women’s viagra’ — should be approved to treat low libido in women.
If approved, the drug would be marketed as treatment for hypoactive sexual desire disorder, which is said to cause a low sex drive in women. Some supporters argue the drug has a role in gender equality and that women do not have the same resources as men to deal with various degrees of sexual dysfunction.
The drug, owned by Sprout Pharmaceuticals, has been rejected by the agency two times already. The argument being that its benefit is not notable enough to outweigh its side effects which can include dizziness and nausea.
Other pharmaceutical companies including Pfizer and Procter & Gamble have made attempts at drugs to treat lack of libido among women. So far they have not been successful.
The FDA’s Thursday meeting on flibanserin is open to the public.
- Meet TIME’s Newest Class of Next Generation Leaders
- After Visiting Both Ends of the Earth, I Realized How Much Trouble We’re In
- Google Is Making It Easier to Remove Personal Info From Search
- Oil Companies Posted Huge Profits. Here’s Where The Cash Will Go (Hint: Not Climate)
- Column: We Asked Hundreds of Americans About Abortion. Their Feelings Were Complicated
- A Short History of the Rise, Fall, and Rise Again of the Marcos Family
- Long-Lasting Birth Control Is Already Hard to Get. Advocates Worry It May Only Get Worse
- Who Should Be on the 2022 TIME100? Vote Now